Overview

A Study of Genetic and Environmental Factors and Their Effect on Response to Treatment With Lucentis (Ranibizumab) for Wet AMD

Status:
Completed

Trial end date:
2010-04-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to understand whether genes or certain factors in the environment determine how eyes will respond to Lucentis (ranibizumab) treatment. For example, whether having variants within specific genes means that a patient is likely to get better vision from treatment than another patient with different genes.

Phase:

Phase 3

Details

Lead Sponsor:

Oregon Health and Science University

Treatments:

Ranibizumab